help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on October 30, 2007
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-1191
A more recent version of this article appeared on January 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
93/1/61    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dekkers, O. M.
Right arrow Articles by Vandenbroucke, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dekkers, O. M.
Right arrow Articles by Vandenbroucke, J. P.
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Diabetes and Insulin

Submitted on May 30, 2007
Accepted on October 24, 2007

Mortality in acromegaly: a meta-analysis

O. M. Dekkers*, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. P. Vandenbroucke

Department of Endocrinology and Metabolic Diseases, Clinical Epidemiology, Leiden University Medical Center, The Netherlands

* To whom correspondence should be addressed. E-mail: o.m.dekkers{at}lumc.nl.

Context. Several studies have assessed mortality risk in patients treated for acromegaly. All studies found a mortality that was higher than expected for the general population, but most of these increases were not statistically significant. For this reason, it is not formally established whether mortality in acromegaly is different form the general population.

Objective. To address the all-cause mortality risk in patients with acromegaly

Design. Meta-analysis

Methods. Sixteen studies on mortality in patients with acromegaly were included. The principal outcome of the meta-analysis was the weighted average of the standardized mortality ratio (SMR) of all studies. Additionally, we performed a subgroup analysis of studies in which more than 80% of the patients was treated by transsphenoidal approach.

Results. The weighted mean of the SMR from all 16 studies was 1.72 (95% CI 1.62–1.83). In studies with transsphenoidal surgery as the primary therapy the weighted mean of the SMR was 1.32 (95% CI 1.12–1.56).

Conclusions. This meta-analysis shows increased all-cause mortality in acromegalic patients compared with the general population even after transsphenoidal surgery.
Key words: Acromegaly • mortality • meta-analysis




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. Beckers
Does Preoperative Somatostatin Analog Treatment Improve Surgical Cure Rates in Acromegaly? A New Look at an Old Question
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2975 - 2977.
[Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
I M Holdaway, M J Bolland, and G D Gamble
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
Eur. J. Endocrinol., August 1, 2008; 159(2): 89 - 95.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society